At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 25 enrolled
Drug / intervention
ACAM2000biological
Likely dose
ACAM2000 2.5µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous (VIGIV)
In Brief
A Phase 3 clinical trial evaluating ACAM2000 for Smallpox Vaccine Adverse Reaction. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The purpose of this study is to vaccinate plasma donors with ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmallpox Vaccine Adverse Reaction
CountriesUnited States
CollaboratorsCenters for Disease Control and Prevention
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2010
Enrollment StartSep 2010
Primary CompletionFeb 2012
TodayJul 2026
First PostedJul 8, 2010
Enrollment StartSep 13, 2010
Primary CompletionFeb 14, 2012
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 16.0 years ago
Interventions
ACAM2000biological
Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.